Last reviewed · How we verify
CDX-011
At a glance
| Generic name | CDX-011 |
|---|---|
| Sponsor | Celldex Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Rash maculo-papular
- Mucositis oral
- Nausea
- Pain
- Infections and infestations - Other, specify
- Lymphocyte count decreased
- Neutrophil count decreased
- Anorexia
- Hypokalemia
- Hypophosphatemia
- Somnolence
- Rash acneiform
Key clinical trials
- A Study to Determine the Safety and Effectiveness of the Investigational Cellular Therapy GCAR1 in a Patient With Alveolar Soft Part Sarcoma (EARLY_PHASE1)
- CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma (EARLY_PHASE1)
- Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer (EARLY_PHASE1)
- Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma (PHASE2)
- Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma (PHASE2)
- A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma (PHASE2)
- Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung (PHASE1, PHASE2)
- Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CDX-011 CI brief — competitive landscape report
- CDX-011 updates RSS · CI watch RSS
- Celldex Therapeutics portfolio CI